Seroprevalence of SARS-CoV-2 in Niger State: Pilot Cross-Sectional Study.

JMIRx med Pub Date : 2023-10-17 DOI:10.2196/29587
Hussaini Majiya, Mohammed Aliyu-Paiko, Vincent Tochukwu Balogu, Dickson Achimugu Musa, Ibrahim Maikudi Salihu, Abdullahi Abubakar Kawu, Ishaku Yakubu Bashir, Aishat Rabiu Sani, John Baba, Amina Tako Muhammad, Fatimah Ladidi Jibril, Ezekiel Bala, Nuhu George Obaje, Yahaya Badeggi Aliyu, Ramatu Gogo Muhammad, Hadiza Mohammed, Usman Naji Gimba, Abduljelili Uthman, Hadiza Muhammad Liman, Sule Alfa Alhaji, Joseph Kolo James, Muhammad Muhammad Makusidi, Mohammed Danasabe Isah, Ibrahim Abdullahi, Umar Ndagi, Bala Waziri, Chindo Ibrahim Bisallah, Naomi John Dadi-Mamud, Kolo Ibrahim, Abu Kasim Adamu
{"title":"Seroprevalence of SARS-CoV-2 in Niger State: Pilot Cross-Sectional Study.","authors":"Hussaini Majiya,&nbsp;Mohammed Aliyu-Paiko,&nbsp;Vincent Tochukwu Balogu,&nbsp;Dickson Achimugu Musa,&nbsp;Ibrahim Maikudi Salihu,&nbsp;Abdullahi Abubakar Kawu,&nbsp;Ishaku Yakubu Bashir,&nbsp;Aishat Rabiu Sani,&nbsp;John Baba,&nbsp;Amina Tako Muhammad,&nbsp;Fatimah Ladidi Jibril,&nbsp;Ezekiel Bala,&nbsp;Nuhu George Obaje,&nbsp;Yahaya Badeggi Aliyu,&nbsp;Ramatu Gogo Muhammad,&nbsp;Hadiza Mohammed,&nbsp;Usman Naji Gimba,&nbsp;Abduljelili Uthman,&nbsp;Hadiza Muhammad Liman,&nbsp;Sule Alfa Alhaji,&nbsp;Joseph Kolo James,&nbsp;Muhammad Muhammad Makusidi,&nbsp;Mohammed Danasabe Isah,&nbsp;Ibrahim Abdullahi,&nbsp;Umar Ndagi,&nbsp;Bala Waziri,&nbsp;Chindo Ibrahim Bisallah,&nbsp;Naomi John Dadi-Mamud,&nbsp;Kolo Ibrahim,&nbsp;Abu Kasim Adamu","doi":"10.2196/29587","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The COVID-19 pandemic caused by SARS-CoV-2 is causing ongoing human and socioeconomic losses.</p><p><strong>Objective: </strong>To know how far the virus has spread in Niger State, Nigeria, a pilot study was carried out to determine the SARS-CoV-2 seroprevalence, patterns, dynamics, and risk factors in the state.</p><p><strong>Methods: </strong>A cross-sectional study design and clustered, stratified random sampling strategy were used to select 185 test participants across the state. SARS-CoV-2 IgG and IgM rapid test kits (colloidal gold immunochromatography lateral flow system) were used to determine the presence or absence of antibodies to the virus in the blood of sampled participants across Niger State from June 26 to 30, 2020. The test kits were validated using the blood samples of some of the Nigeria Center for Disease Control-confirmed positive and negative COVID-19 cases in the state. SARS-CoV-2 IgG and IgM test results were entered into the Epi Info questionnaire administered simultaneously with each test. Epi Info was then used to calculate the arithmetic mean and percentage, odds ratio, χ2 statistic, and regression at a 95% CI of the data generated.</p><p><strong>Results: </strong>The seroprevalence of SARS-CoV-2 in Niger State was found to be 25.4% (47/185) and 2.2% (4/185) for the positive IgG and IgM results, respectively. Seroprevalence among age groups, genders, and occupations varied widely. The COVID-19 asymptomatic rate in the state was found to be 46.8% (22/47). The risk analyses showed that the chances of infection are almost the same for both urban and rural dwellers in the state. However, health care workers, those who experienced flulike symptoms, and those who had contact with a person who traveled out of Nigeria in the last 6 months (February to June 2020) were at double the risk of being infected with the virus. More than half (101/185, 54.6%) of the participants in this study did not practice social distancing at any time since the pandemic started. Participants' knowledge, attitudes, and practices regarding COVID-19 are also discussed.</p><p><strong>Conclusions: </strong>The observed Niger State SARS-CoV-2 seroprevalence and infection patterns meansuggest that the virus has widely spread, far more SARS-CoV-2 infections have occurred than the reported cases, and there is a high asymptomatic COVID-19 rate across the state.</p>","PeriodicalId":73558,"journal":{"name":"JMIRx med","volume":"4 ","pages":"e29587"},"PeriodicalIF":0.0000,"publicationDate":"2023-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10595504/pdf/","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JMIRx med","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2196/29587","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 4

Abstract

Background: The COVID-19 pandemic caused by SARS-CoV-2 is causing ongoing human and socioeconomic losses.

Objective: To know how far the virus has spread in Niger State, Nigeria, a pilot study was carried out to determine the SARS-CoV-2 seroprevalence, patterns, dynamics, and risk factors in the state.

Methods: A cross-sectional study design and clustered, stratified random sampling strategy were used to select 185 test participants across the state. SARS-CoV-2 IgG and IgM rapid test kits (colloidal gold immunochromatography lateral flow system) were used to determine the presence or absence of antibodies to the virus in the blood of sampled participants across Niger State from June 26 to 30, 2020. The test kits were validated using the blood samples of some of the Nigeria Center for Disease Control-confirmed positive and negative COVID-19 cases in the state. SARS-CoV-2 IgG and IgM test results were entered into the Epi Info questionnaire administered simultaneously with each test. Epi Info was then used to calculate the arithmetic mean and percentage, odds ratio, χ2 statistic, and regression at a 95% CI of the data generated.

Results: The seroprevalence of SARS-CoV-2 in Niger State was found to be 25.4% (47/185) and 2.2% (4/185) for the positive IgG and IgM results, respectively. Seroprevalence among age groups, genders, and occupations varied widely. The COVID-19 asymptomatic rate in the state was found to be 46.8% (22/47). The risk analyses showed that the chances of infection are almost the same for both urban and rural dwellers in the state. However, health care workers, those who experienced flulike symptoms, and those who had contact with a person who traveled out of Nigeria in the last 6 months (February to June 2020) were at double the risk of being infected with the virus. More than half (101/185, 54.6%) of the participants in this study did not practice social distancing at any time since the pandemic started. Participants' knowledge, attitudes, and practices regarding COVID-19 are also discussed.

Conclusions: The observed Niger State SARS-CoV-2 seroprevalence and infection patterns meansuggest that the virus has widely spread, far more SARS-CoV-2 infections have occurred than the reported cases, and there is a high asymptomatic COVID-19 rate across the state.

Abstract Image

尼日尔州严重急性呼吸系统综合征冠状病毒2型的血清流行率:试点横断面研究。
背景:由SARS-CoV-2引起的新冠肺炎大流行正在造成持续的人类和社会经济损失。目的:为了了解该病毒在尼日利亚尼日尔州的传播程度,进行了一项试点研究,以确定该州的严重急性呼吸系统综合征冠状病毒2型血清流行率、模式、动态和风险因素。方法:采用横断面研究设计和聚类分层随机抽样策略,在全州范围内选择185名测试参与者。2020年6月26日至30日,使用严重急性呼吸系统综合征冠状病毒2型IgG和IgM快速检测试剂盒(胶体金免疫层析侧流系统)来确定尼日尔州采样参与者血液中是否存在病毒抗体。这些检测试剂盒是使用尼日利亚疾病控制中心的一些血液样本进行验证的,这些样本证实了该州新冠肺炎阳性和阴性病例。将严重急性呼吸系统综合征冠状病毒2型IgG和IgM检测结果输入与每次检测同时进行的Epi-Info问卷中。然后使用Epi-Info计算算术平均值和百分比、比值比、χ2统计和95%CI的回归数据。结果:IgG和IgM阳性结果显示,尼日尔州严重急性呼吸系统综合征冠状病毒2型的血清流行率分别为25.4%(47/185)和2.2%(4/185)。年龄组、性别和职业的血清流行率差异很大。该州新冠肺炎无症状率为46.8%(22/47)。风险分析表明,该州城市和农村居民感染的几率几乎相同。然而,医护人员、出现流感样症状的人以及在过去6个月(2020年2月至6月)内与离开尼日利亚的人有过接触的人感染病毒的风险是原来的两倍。自疫情开始以来,这项研究中超过一半(101/185,54.6%)的参与者在任何时候都没有保持社交距离。还讨论了参与者对新冠肺炎的知识、态度和实践。结论:观察到的尼日尔州SARS-CoV-2血清流行率和感染模式表明,该病毒已广泛传播,发生的SARS-CoV-2感染病例远多于报告病例,全州无症状新冠肺炎发病率很高。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信